Display options
Cite
Jena A, Renjen PN, Taneja S, et al. Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay. Indian J Radiol Imaging. 2015;25(4):342-52doi: 10.4103/0971-3026.169449.
Jena, A., Renjen, P. N., Taneja, S., Gambhir, A., & Negi, P. (2015). Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay. The Indian journal of radiology & imaging, 25(4), 342-52. https://doi.org/10.4103/0971-3026.169449
Jena, Amarnath, et al. "Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay." The Indian journal of radiology & imaging vol. 25,4 (2015): 342-52. doi: https://doi.org/10.4103/0971-3026.169449
Jena A, Renjen PN, Taneja S, Gambhir A, Negi P. Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay. Indian J Radiol Imaging. 2015 Oct-Dec;25(4):342-52. doi: 10.4103/0971-3026.169449. PMID: 26752814; PMCID: PMC4693381.
Copy Download .nbib Format: NLM
Share it on

Indian J Radiol Imaging. 2015 Oct-Dec;25(4):342-52. doi: 10.4103/0971-3026.169449.

Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay.

The Indian journal of radiology & imaging

Amarnath Jena, Pushpendra Nath Renjen, Sangeeta Taneja, Aashish Gambhir, Pradeep Negi

Affiliations

  1. PET SUITE, Department of Molecular Imaging and Nuclear Medicine, Indraprastha Apollo Hospitals, New Delhi, India.
  2. PET SUITE, Department of Neurology, Indraprastha Apollo Hospitals, New Delhi, India.

PMID: 26752814 PMCID: PMC4693381 DOI: 10.4103/0971-3026.169449

Abstract

Dementia, caused by irreversible neurodegenerative disorders such as Alzheimer's disease or reversible non-degenerative conditions, is rapidly becoming one of the most alarming health problems in our aging society. This cognitive disorder associated with a multitude of clinical differentials with overlapping clinical, pathological, and imaging features is difficult to diagnose and treat, as it often presents late after significant neuronal damage has already occurred. Novel disease-modifying treatments being developed will have to be corroborated with innovative imaging biomarkers so that earlier reliable diagnosis can be made and treatment initiated upon. Along with new specific PET radiotracers, integrated PET/MRI with combined methodological advantage and simultaneously acquired structural-cum-functional information may help achieve this goal. The present pictorial essay details our experiences with PET/MRI in dementing disorders, along with reviewing recent advances and future scope.

Keywords: 18F-FDG; Alzheimer's disease; amyloid PET; dementia; integrated PET/MRI; vascular dementia

References

  1. AJNR Am J Neuroradiol. 2004 Feb;25(2):195-200 - PubMed
  2. J Nucl Med. 2011 Dec;52(12 ):1914-22 - PubMed
  3. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12 ):2227-34 - PubMed
  4. Radiology. 2010 Sep;256(3):932-42 - PubMed
  5. Lancet Neurol. 2013 Apr;12(4):357-67 - PubMed
  6. Neuroimage Clin. 2015 May 21;8:583-93 - PubMed
  7. J Nucl Med. 2010 Sep;51(9):1431-8 - PubMed
  8. J Nucl Med. 2006 Apr;47(4):639-47 - PubMed
  9. Lancet. 2006 Apr 15;367(9518):1262-70 - PubMed
  10. Arch Intern Med. 2003 Oct 13;163(18):2219-29 - PubMed
  11. J Nucl Med. 2010 May;51(5):812-8 - PubMed
  12. J Neuroimmunol. 2004 Dec;157(1-2):153-62 - PubMed
  13. Neuroimaging Clin N Am. 2011 Nov;21(4):737-56, vii - PubMed
  14. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9 - PubMed
  15. J Magn Reson Imaging. 2010 Nov;32(5):1045-53 - PubMed
  16. Neurology. 2001 May 8;56(9):1143-53 - PubMed
  17. Med Clin North Am. 2006 Sep;90(5):769-87 - PubMed
  18. PLoS One. 2013;8(3):e58442 - PubMed
  19. Ther Umsch. 2015 Apr;72(4):261-9 - PubMed
  20. Lancet Neurol. 2010 Jan;9(1):119-28 - PubMed
  21. Psychiatr Clin North Am. 2015 Jun;38(2):281-94 - PubMed
  22. Neurol India. 2014 Sep-Oct;62(5):487-91 - PubMed
  23. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):794-805 - PubMed
  24. Prog Neurobiol. 2013 Sep;108:21-43 - PubMed
  25. J Neurol. 1995 Jul;242(7):466-71 - PubMed
  26. Brain. 2008 Mar;131(Pt 3):665-80 - PubMed
  27. Clin Nucl Med. 2014 Jun;39(6):e336-9 - PubMed
  28. Front Neuroenergetics. 2014 Jan 09;5:13 - PubMed
  29. PLoS One. 2011 Mar 23;6(3):e18111 - PubMed
  30. Eur J Radiol. 2014 Jul;83(7):1269-74 - PubMed
  31. J Neurol. 2002 Jun;249(6):699-705 - PubMed
  32. PLoS One. 2012;7(3):e33182 - PubMed
  33. Neurologia. 2015 Apr;30(3):144-52 - PubMed
  34. Neuroepidemiology. 1995;14(5):240-57 - PubMed
  35. Curr Med Chem. 2015;22(33):3789-806 - PubMed
  36. Alzheimers Dement. 2011 May;7(3):270-9 - PubMed
  37. Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 - PubMed
  38. Brain. 2010 Nov;133(11):3336-48 - PubMed
  39. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407 - PubMed
  40. CNS Neurol Disord Drug Targets. 2015;14(7):872-9 - PubMed
  41. Aging (Milano). 2001 Jun;13(3):203-9 - PubMed
  42. BMC Fam Pract. 2010 Jul 01;11:52 - PubMed
  43. Neurotherapeutics. 2011 Jan;8(1):82-92 - PubMed
  44. AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1551-62 - PubMed

Publication Types